Fig. 4: NMR metabolomics identifies altered mechanism of action in d-pleurocidin analogues. | Communications Biology

Fig. 4: NMR metabolomics identifies altered mechanism of action in d-pleurocidin analogues.

From: A pleurocidin analogue with greater conformational flexibility, enhanced antimicrobial potency and in vivo therapeutic efficacy

Fig. 4: NMR metabolomics identifies altered mechanism of action in d-pleurocidin analogues.

Volcano plots obtained from liquid state 1H NMR of spent bacterial culture reveal the metabolic strategy of EMRSA-15 in MHB (a), challenged with d-pleurocidin (g), d-pleurocidin-KR (h) or d-pleurocidin-VA (i), or in RPMI (b). Tentative assignments are indicated by (t). The major catabolic pathways of EMRSA-15 are shown for context with key enzymes: FDH formate dehydrogenase, SDH succinate dehydrogenase, NR nitrate reductase, NiR nitrite reductase (f). 1H HR-MAS NMR of bacterial pellets reveals the effect on cellular metabolites of growth in these media (c) or challenge with antibiotics in MHB (j–l). Production of ROS/RNS when challenged by antibiotics, as monitored by DCFH-DA, is shown for MHB (d) and RPMI (e). Data points are averages from six distinct colonies. Boxes represent 1 SE and whiskers 1.5 SE of three independent repeats. Significance is relative to the d-pleurocidin challenge (*p < 0.05; **p < 0.01).

Back to article page